Exane Derivatives lifted its holdings in shares of Xylem Inc (NYSE:XYL) by 1,560.7% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 24,478 shares of the industrial products company’s stock after purchasing an additional 23,004 shares during the quarter. Exane Derivatives’ holdings in Xylem were worth $1,669,000 as of its most recent SEC filing.
Several other hedge funds have also bought and sold shares of XYL. Sentry Investment Management LLC raised its position in Xylem by 1.2% in the second quarter. Sentry Investment Management LLC now owns 11,839 shares of the industrial products company’s stock valued at $656,000 after purchasing an additional 137 shares during the period. Gyroscope Capital Management Group LLC raised its position in Xylem by 7.8% in the second quarter. Gyroscope Capital Management Group LLC now owns 4,387 shares of the industrial products company’s stock valued at $243,000 after purchasing an additional 316 shares during the period. Nordea Investment Management AB raised its position in Xylem by 3.3% in the second quarter. Nordea Investment Management AB now owns 15,355 shares of the industrial products company’s stock valued at $851,000 after purchasing an additional 494 shares during the period. Advisor Group Inc. raised its position in Xylem by 18.3% in the second quarter. Advisor Group Inc. now owns 3,592 shares of the industrial products company’s stock valued at $198,000 after purchasing an additional 555 shares during the period. Finally, Global X MANAGEMENT CO LLC raised its position in Xylem by 13.4% in the third quarter. Global X MANAGEMENT CO LLC now owns 6,849 shares of the industrial products company’s stock valued at $429,000 after purchasing an additional 808 shares during the period. Institutional investors and hedge funds own 85.07% of the company’s stock.
In other Xylem news, insider Tomas Brannemo sold 2,260 shares of Xylem stock in a transaction that occurred on Tuesday, December 19th. The shares were sold at an average price of $67.75, for a total transaction of $153,115.00. Following the transaction, the insider now directly owns 10,975 shares in the company, valued at approximately $743,556.25. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Steven R. Loranger sold 47,712 shares of Xylem stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $68.10, for a total transaction of $3,249,187.20. Following the transaction, the director now owns 68,843 shares in the company, valued at $4,688,208.30. The disclosure for this sale can be found here. In the last three months, insiders have sold 75,455 shares of company stock worth $5,166,873. 0.75% of the stock is owned by corporate insiders.
Shares of Xylem Inc (NYSE XYL) opened at $71.93 on Tuesday. The firm has a market capitalization of $12,719.27, a P/E ratio of 39.09, a PEG ratio of 1.35 and a beta of 1.20. The company has a current ratio of 1.88, a quick ratio of 1.41 and a debt-to-equity ratio of 0.87. Xylem Inc has a twelve month low of $46.95 and a twelve month high of $76.81.
Xylem (NYSE:XYL) last announced its earnings results on Thursday, February 1st. The industrial products company reported $0.76 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.76. Xylem had a return on equity of 17.95% and a net margin of 7.03%. The firm had revenue of $1.28 billion for the quarter, compared to analysts’ expectations of $1.27 billion. During the same quarter in the previous year, the company earned $0.66 earnings per share. The firm’s quarterly revenue was up 16.6% compared to the same quarter last year. sell-side analysts forecast that Xylem Inc will post 2.91 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, March 15th. Investors of record on Thursday, February 15th will be issued a dividend of $0.21 per share. This is a boost from Xylem’s previous quarterly dividend of $0.18. The ex-dividend date is Wednesday, February 14th. This represents a $0.84 annualized dividend and a yield of 1.17%. Xylem’s payout ratio is presently 39.13%.
Several research analysts have commented on XYL shares. Oppenheimer reissued a “buy” rating on shares of Xylem in a research report on Tuesday, October 31st. Boenning Scattergood reaffirmed a “buy” rating on shares of Xylem in a research report on Friday, December 15th. Canaccord Genuity reaffirmed a “hold” rating and set a $65.00 target price on shares of Xylem in a research report on Monday, December 11th. BMO Capital Markets reaffirmed a “buy” rating and set a $86.00 target price on shares of Xylem in a research report on Friday, February 2nd. Finally, Zacks Investment Research lowered Xylem from a “buy” rating to a “hold” rating in a research report on Wednesday, December 6th. Five investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $70.08.
TRADEMARK VIOLATION WARNING: “Xylem Inc (XYL) Shares Bought by Exane Derivatives” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The original version of this article can be read at https://www.dispatchtribunal.com/2018/02/13/xylem-inc-xyl-position-boosted-by-exane-derivatives.html.
Xylem Inc is a water technology company. The Company designs, manufactures and services engineered solutions across a range of critical applications. It is an equipment and service provider for water and wastewater applications with a portfolio of products and services addressing the cycle of water, from collection, distribution and use to the return of water to the environment.
Receive News & Ratings for Xylem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xylem and related companies with MarketBeat.com's FREE daily email newsletter.